Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression

被引:8
作者
Dubois, L.
Dresselaers, T.
Landuyt, W.
Paesmans, K.
Mengesha, A.
Wouters, B. G.
Van Hecke, P.
Theys, J.
Lambin, P.
机构
[1] Univ Maastricht, GROW Res Inst, Dept Radiat Oncol, Maastro Lab, NL-6200 MD Maastricht, Netherlands
[2] Katholieke Univ Leuven, Biomed NMR Unit, B-3000 Louvain, Belgium
[3] Katholieke Univ Leuven, Lab Expt OncolRadiobiol, B-3000 Louvain, Belgium
关键词
F-19-MRS; Salmonella typhimurium; gene therapy; cytosine deaminase; xenograft human tumour;
D O I
10.1038/sj.bjc.6603624
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The potential utility of tumour-selective 5-fluorouracil treatment using attenuated Salmonella serovar typhimurium recombinant for cytosine deaminase (TAPET-CD) has been documented in experimental settings. The present data demonstrate that in vivo F-19-magnetic resonance spectroscopy measurements allow the outcome prediction of this prokaryotic-based therapy, demonstrating the necessity of non-invasive real-time imaging techniques for treatment monitoring.
引用
收藏
页码:758 / 761
页数:4
相关论文
共 13 条
  • [1] Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours
    Dresselaers, T
    Theys, J
    Nuyts, S
    Wouters, B
    de Bruijn, E
    Anné, J
    Lambin, P
    Van Hecke, P
    Landuyt, W
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (09) : 1796 - 1801
  • [2] Evaluation of hypoxia in an experimental rat tumour model by [18F]Fluoromisonidazole PET and immunohistochemistry
    Dubois, L
    Landuyt, W
    Haustermans, K
    Dupont, P
    Bormans, G
    Vermaelen, P
    Flamen, P
    Verbeken, E
    Mortelmans, L
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (11) : 1947 - 1954
  • [3] Kamm YJL, 1996, MAGNET RESON MED, V36, P445
  • [4] Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent
    King, I
    Bermudes, D
    Lin, S
    Belcourt, M
    Pike, J
    Troy, K
    Le, T
    Ittensohn, M
    Mao, J
    Lang, WS
    Runyan, JD
    Luo, X
    Li, ZJ
    Zheng, LM
    [J]. HUMAN GENE THERAPY, 2002, 13 (10) : 1225 - 1233
  • [5] Fluorine-19 or phosphorus-31 NMR spectroscopy: A suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs
    Martino, R
    Gilard, V
    Desmoulin, F
    Malet-Martino, M
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (05) : 871 - 891
  • [6] Mei SP, 2002, ANTICANCER RES, V22, P3261
  • [7] MINTON NP, 1995, FEMS MICROBIOL REV, V17, P357, DOI 10.1016/0168-6445(95)00009-2
  • [8] Pilot trial of genetically modified, attenuated Salmonella expressing the E-coli cytosine deaminase gene in refractory cancer patients
    Nemunaitis, J
    Cunningham, C
    Senzer, N
    Kuhn, J
    Cramm, J
    Litz, C
    Cavagnolo, R
    Cahill, A
    Clairmont, C
    Sznol, M
    [J]. CANCER GENE THERAPY, 2003, 10 (10) : 737 - 744
  • [9] Schlemmer HP, 1999, CANCER RES, V59, P2363
  • [10] Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
    Theys, J
    Landuyt, W
    Nuyts, S
    Van Mellaert, L
    van Oosterom, A
    Lambin, P
    Anné, J
    [J]. CANCER GENE THERAPY, 2001, 8 (04) : 294 - 297